| 11.1786 0.144 (1.3%) | 08-19 12:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.78 |
1-year : | 17.26 |
| Resists | First : | 12.65 |
Second : | 14.78 |
| Pivot price | 10.87 |
|||
| Supports | First : | 10.87 |
Second : | 9.77 |
| MAs | MA(5) : | 11.18 |
MA(20) : | 10.75 |
| MA(100) : | 10.76 |
MA(250) : | 15.26  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 60.8 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 39.2 | Low : | 8.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVNO ] has closed below upper band by 27.0%. Bollinger Bands are 21.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.5 - 12.58 | 12.58 - 12.64 |
| Low: | 10.58 - 10.65 | 10.65 - 10.71 |
| Close: | 10.93 - 11.05 | 11.05 - 11.15 |
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Fri, 14 Aug 2026
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
Thu, 30 Jul 2026
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
Thu, 30 Jul 2026
enVVeno Medical Corp Q2 2026: Revenue —, Net loss $3.6M, EPS $(5.37) — 10-Q Summary - TradingView
Mon, 27 Jul 2026
enVVeno Medical Corp expected to post a loss of $4.69 a share - Earnings Preview - TradingView
Mon, 22 Jun 2026
FDA-cleared venous valve study takes center stage at enVVeno webinar - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 13 (%) |
| Held by Institutions | 24.8 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -24.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 41.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.7 % |
| Return on Equity (ttm) | -58.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -25.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.46 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|